TOP TIERMARKET NEWSWIRE
Movers explained · 2026-07-28

Archived explainer. For the current picture see today's GOSS page.

Why Is GOSSAMER BIO INC (GOSS) Stock Moving Today?

By the Top Tier Newswire AI Desk · July 28, 2026 at 5:14 AM ET · reviewed against 7 wire stories

GOSSAMER BIO INC (GOSS) is drawing unusual attention today. Our newswire has captured 7 stories on GOSS across 7 sources in the last 36 hours, with AI sentiment reading bullish (avg 59/100).

Why GOSS stock is moving today

Gossamer Bio (GOSS) shares are rising today following key developments regarding the regulatory path for its lead drug candidate, seralutinib, and the reacquisition of global rights to the therapy. The company announced that the FDA has outlined a potential timeline for a September 2026 New Drug Application (NDA) filing. Additionally, Gossamer Bio has regained full control of seralutinib, which is expected to enhance its strategic flexibility and strengthen its capital position.

What Happened

The company filed a Form 8-K with the SEC on July 27, 2026, disclosing the reacquisition of worldwide rights to seralutinib and outlining a clear regulatory path forward. This development follows feedback from the FDA, which has provided guidance that could lead to an NDA submission by September. Leerink upgraded the stock rating based on this regulatory progress. The company also announced a restructuring of its debt and secured major investor approvals, which contributed to the positive market reaction.

What The Data Shows

GOSS has a market cap of $66.5 million and has been unprofitable, with a trailing twelve-month (TTM) net margin of -324.8% and an EPS of -0.78. The stock has declined by 17.0% over the last 8 trading sessions, moving from $0.22 to $0.18. Its 52-week range is between $0.11 and $3.87. The stock has a beta of 2.04, indicating higher volatility compared to the market. The recent news appears to have shifted investor sentiment, with the stock showing strength after the announcements.

What To Watch

The company has not provided an upcoming earnings date. Investors should monitor the breadth of coverage and any further regulatory updates related to seralutinib as the FDA timeline unfolds.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.

GOSS by the numbers

7 sessions: -16.95%Coverage: 7 stories / 7 sourcesAI sentiment: 59/100 (bullish)Mkt cap: $66M52w: $0.11 to $3.87
GOSS · Jul 28 session (5-min) · +2.61% vs prior close · updated 8:49 PM ET
$0.19$0.25$0.32prev close $0.20$0.207:00 AM10:13 AM1:27 PM4:41 PM7:55 PM7:00 AM · $0.267:05 AM · $0.257:10 AM · $0.267:15 AM · $0.267:20 AM · $0.267:25 AM · $0.267:30 AM · $0.267:35 AM · $0.277:40 AM · $0.277:45 AM · $0.277:50 AM · $0.277:55 AM · $0.278:00 AM · $0.318:05 AM · $0.298:10 AM · $0.308:15 AM · $0.298:20 AM · $0.288:25 AM · $0.288:30 AM · $0.288:35 AM · $0.278:40 AM · $0.278:45 AM · $0.278:50 AM · $0.278:55 AM · $0.269:00 AM · $0.279:05 AM · $0.269:10 AM · $0.279:15 AM · $0.269:20 AM · $0.269:25 AM · $0.279:30 AM · $0.239:35 AM · $0.239:40 AM · $0.249:45 AM · $0.249:50 AM · $0.239:55 AM · $0.2310:00 AM · $0.2210:05 AM · $0.2210:10 AM · $0.2210:15 AM · $0.2210:20 AM · $0.2210:25 AM · $0.2110:30 AM · $0.2110:35 AM · $0.2110:40 AM · $0.2110:45 AM · $0.2210:50 AM · $0.2110:55 AM · $0.2111:00 AM · $0.2111:05 AM · $0.2111:10 AM · $0.2111:15 AM · $0.2211:20 AM · $0.2211:25 AM · $0.2111:30 AM · $0.2111:35 AM · $0.2111:40 AM · $0.2311:45 AM · $0.2211:50 AM · $0.2211:55 AM · $0.2112:00 PM · $0.2112:05 PM · $0.2112:10 PM · $0.2112:15 PM · $0.2112:20 PM · $0.2112:25 PM · $0.2012:30 PM · $0.2012:35 PM · $0.2012:40 PM · $0.2012:45 PM · $0.2012:50 PM · $0.2112:55 PM · $0.201:00 PM · $0.201:05 PM · $0.201:10 PM · $0.201:15 PM · $0.211:20 PM · $0.211:25 PM · $0.201:30 PM · $0.211:35 PM · $0.211:40 PM · $0.201:45 PM · $0.201:50 PM · $0.201:55 PM · $0.202:00 PM · $0.202:05 PM · $0.202:10 PM · $0.202:15 PM · $0.192:20 PM · $0.192:25 PM · $0.202:30 PM · $0.202:35 PM · $0.192:40 PM · $0.192:45 PM · $0.192:50 PM · $0.192:55 PM · $0.203:00 PM · $0.203:05 PM · $0.203:10 PM · $0.203:15 PM · $0.203:20 PM · $0.193:25 PM · $0.203:30 PM · $0.203:35 PM · $0.203:40 PM · $0.203:45 PM · $0.193:50 PM · $0.203:55 PM · $0.214:00 PM · $0.204:05 PM · $0.214:10 PM · $0.204:15 PM · $0.204:20 PM · $0.204:25 PM · $0.204:30 PM · $0.204:35 PM · $0.204:40 PM · $0.204:45 PM · $0.204:50 PM · $0.204:55 PM · $0.205:00 PM · $0.205:05 PM · $0.205:10 PM · $0.215:15 PM · $0.215:20 PM · $0.235:25 PM · $0.225:30 PM · $0.225:35 PM · $0.225:40 PM · $0.225:45 PM · $0.215:50 PM · $0.215:55 PM · $0.216:00 PM · $0.216:05 PM · $0.216:10 PM · $0.216:15 PM · $0.216:20 PM · $0.216:25 PM · $0.226:30 PM · $0.216:35 PM · $0.216:40 PM · $0.216:45 PM · $0.216:50 PM · $0.216:55 PM · $0.217:00 PM · $0.217:05 PM · $0.217:10 PM · $0.217:15 PM · $0.207:20 PM · $0.207:25 PM · $0.207:30 PM · $0.207:35 PM · $0.207:40 PM · $0.207:45 PM · $0.207:50 PM · $0.217:55 PM · $0.20
AI sentiment, last 36h · averaged over 7 stories · 59/100 bullish
AI sentiment 59/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 7 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agopublishStockTitan · sentiment 56 · Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update | GOSS Stock NewsStockTitan · 56Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Relate…Investing.com Markets · sentiment 50 · Why is Gossamer Bio stock surging today?Investing.com Markets · 50Why is Gossamer Bio stock surging today?InvestorsHub · sentiment 68 · Gossamer Bio shares jump after FDA update and seralutinib rights returnInvestorsHub · 68Gossamer Bio shares jump after FDA update and seralutinib rights returnMarketChameleon · sentiment 73 · Gossamer Bio Locks in Global Rights and Regulatory Path for Seralutinib—Strengthened Balance Sheet Provides Flexibility July 27, 2026MarketChameleon · 73Gossamer Bio Locks in Global Rights and Regulatory Path for Seralutinib—Strengthened Bala…Seeking Alpha · sentiment 56 · Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Capital Structure Updates TranscriptSeeking Alpha · 56Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progr…SEC 8-K · sentiment 50 · Gossamer Bio, Inc. (GOSS) files 8-KSEC 8-K · 50Gossamer Bio, Inc. (GOSS) files 8-KInvesting.com Analyst Ratings · sentiment 61 · Leerink upgrades Gossamer Bio stock rating on FDA feedbackInvesting.com Analyst Ratings · 61Leerink upgrades Gossamer Bio stock rating on FDA feedback
2d agoInvesting.com Analyst RatingsBULLISH 61Analyst

Leerink upgrades Gossamer Bio stock rating on FDA feedback

Leerink upgrades Gossamer Bio stock rating on FDA feedback

2d agoSEC 8-KNEUTRAL 50General

Gossamer Bio, Inc. (GOSS) files 8-K

Filed: 2026-07-27 AccNo: 0001728117-26-000064 Size: 442 KB Item 1.01: Entry into a Material Definitive Agreement Item 1.02: Termination of a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

2d agoSeeking AlphaBULLISH 56General

Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Capital Structure Updates Transcript

Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Capital Structure Updates July 27, 2026 8:00 AM EDTCompany...

2d agoMarketChameleonBULLISH 73Product/PR

Gossamer Bio Locks in Global Rights and Regulatory Path for Seralutinib—Strengthened Balance Sheet Provides Flexibility July 27, 2026

Gossamer Bio firms up its future with a clear FDA submission timeline for seralutinib, reacquires worldwide rights to the drug, and reinforces its capital structure following major investor approvals and convertible note exchanges.

2d agoInvestorsHubBULLISH 68Product/PR

Gossamer Bio shares jump after FDA update and seralutinib rights return

Gossamer Bio (NASDAQ:GOSS) shares jumped after the FDA outlined a path toward a September NDA filing for seralutinib and the company regained worldwide rights to the therapy while reducing its debt.

2d agoInvesting.com MarketsNEUTRAL 50General

Why is Gossamer Bio stock surging today?

Why is Gossamer Bio stock surging today?

2d agoStockTitanBULLISH 56General

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update | GOSS Stock News

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on GOSS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier GOSS move explainers: 2026-07-28 · 2026-07-27